Renal Cancer

The diagnosis and management of renal cell carcinoma have changed remarkably rapidly. Although the incidence of renal cell carcinoma has been increasing, survival has improved substantially. As incidental diagnosis of small indolent cancers has become more frequent, active surveillance, robot-assisted nephron-sparing surgical techniques, and minimally invasive procedures, such as thermal ablation, have gained popularity. Despite progression in cancer control and survival, locally advanced disease and distant metastases are still diagnosed in a notable proportion of patients. An integrated management strategy that includes surgical debulking and systemic treatment with well established targeted biological drugs has improved the care of patients. Nevertheless, uncertainties, controversies, and research questions remain. Further advances are expected from translational and clinical studies.

[1]  Ricardo A Rendon,et al.  Active surveillance as the preferred management option for small renal masses. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[2]  D. Parekh,et al.  Tolerance of the human kidney to isolated controlled ischemia. , 2013, Journal of the American Society of Nephrology : JASN.

[3]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[4]  Walter Artibani,et al.  Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. , 2009, European urology.

[5]  S. Horenblas,et al.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  P. Tamboli,et al.  Partial nephrectomy in the setting of metastatic renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Makarewicz,et al.  The value of postoperative radiotherapy in advanced renal cell cancer. , 1998, Neoplasma.

[8]  W. Meinhardt,et al.  Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients , 2011, World Journal of Urology.

[9]  E. Sacco,et al.  Paraneoplastic Syndromes in Patients with Urological Malignancies , 2009, Urologia Internationalis.

[10]  E. Messing,et al.  Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. , 2014, European urology.

[11]  W Marston Linehan,et al.  New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease , 2015, Clinical Cancer Research.

[12]  P. Albers,et al.  Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. , 2007, The Journal of urology.

[13]  M. Lacouture,et al.  Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. , 2014, Clinical genitourinary cancer.

[14]  C. la Vecchia,et al.  History of treated hypertension and diabetes mellitus and risk of renal cell cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Jacqmin,et al.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.

[16]  John C Bischof,et al.  The cryobiology of cryosurgical injury. , 2002, Urology.

[17]  R. Sylvester,et al.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2011, European urology.

[18]  G. Sonpavde,et al.  Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. , 2014, Future oncology.

[19]  M. Staehler,et al.  Local treatments for metastases of renal cell carcinoma: a systematic review. , 2014, The Lancet. Oncology.

[20]  K. Katsanos,et al.  Systematic Review and Meta-Analysis of Thermal Ablation Versus Surgical Nephrectomy for Small Renal Tumours , 2014, CardioVascular and Interventional Radiology.

[21]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[22]  A. Evans,et al.  Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. , 2011, European urology.

[23]  B. Rini,et al.  Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Klatte,et al.  Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma , 2014, Korean journal of urology.

[25]  P. Russo,et al.  Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. , 2008, The Urologic clinics of North America.

[26]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[27]  R. Uzzo,et al.  Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. , 2008, The Journal of urology.

[28]  R. Sylvester,et al.  Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. , 2013, European urology.

[29]  R. Sylvester,et al.  A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2007, European urology.

[30]  R. Flanigan,et al.  New modalities for evaluation and surveillance of complex renal cysts. , 2014, The Journal of urology.

[31]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[32]  U. Capitanio,et al.  A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. , 2010, Urology.

[33]  C. Wood,et al.  Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy , 2014, World Journal of Urology.

[34]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[35]  E. Maher,et al.  VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.

[36]  Antonio Lopez-Beltran,et al.  Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.

[37]  R. Uzzo,et al.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Robert G. Uzzo,et al.  Heterogeneity and renal mass biopsy: a review of its role and reliability , 2014, Cancer biology & medicine.

[39]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[40]  R. Uzzo,et al.  Focal therapy for treatment of the small renal mass: dealer's choice or a therapeutic gamble? , 2015, European urology.

[41]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Robert G Uzzo,et al.  The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. , 2009, The Journal of urology.

[43]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[44]  J. Patard,et al.  A comparative population‐based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma , 2010, BJU international.

[45]  L. Jones,et al.  Recent advances in imaging cancer of the kidney and urinary tract. , 2014, Surgical oncology clinics of North America.

[46]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Uzzo,et al.  Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. , 2014, The Journal of urology.

[48]  Marco Bianchi,et al.  Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift , 2012, Annals of Surgical Oncology.

[49]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[50]  Birt-Hogg-Dubé syndrome. , 2013, JAMA.

[51]  W. Marston Linehan,et al.  Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.

[52]  Inderbir S Gill,et al.  Kidney tumor location measurement using the C index method. , 2010, The Journal of urology.

[53]  J. Patard,et al.  Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Gervais,et al.  Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. , 2005, AJR. American journal of roentgenology.

[55]  Y. Funahashi,et al.  Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. , 2009, European urology.

[56]  C. Gross,et al.  The Effect of the Diffusion of the Surgical Robot on the Hospital-level Utilization of Partial Nephrectomy , 2015, Medical care.

[57]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  P. Boracchi,et al.  Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Thompson,et al.  Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. , 2015, European urology.

[60]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[61]  S. Rosenberg,et al.  Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P Kirkbride,et al.  Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[63]  W. Oyen,et al.  Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. , 2013, European urology.

[64]  D. Burr,et al.  Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study , 2008, BMC Cancer.

[65]  A. Volpe,et al.  Can emerging level 1 evidence "discourage" elective nephron-sparing surgery for small renal tumors? , 2011, European urology.

[66]  T. Watnick,et al.  Not all renal cysts are created equal , 2010, The Lancet.

[67]  T. Delea,et al.  Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. , 2015, Journal of managed care & specialty pharmacy.

[68]  R. Motzer,et al.  Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[70]  C. Porta,et al.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[71]  C. Porta,et al.  Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial , 2008 .

[72]  Stephanie Daignault,et al.  Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect , 2006 .

[73]  S. Karami,et al.  A prospective study of alcohol consumption and renal cell carcinoma risk , 2015, International journal of cancer.

[74]  Paul Russo,et al.  Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? , 2009, The Journal of urology.

[75]  Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .

[76]  D. Bottaro,et al.  Hereditary papillary renal carcinoma type I. , 2004, Current molecular medicine.

[77]  R. Uzzo,et al.  Is anatomic complexity associated with renal tumor growth kinetics under active surveillance? , 2015, Urologic oncology.

[78]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[79]  M. Remzi,et al.  Rationale for percutaneous biopsy and histologic characterisation of renal tumours. , 2012, European urology.

[80]  N. Agarwal,et al.  Sequencing Systemic Therapies for Metastatic Kidney Cancer , 2015, Current Treatment Options in Oncology.

[81]  R. Figlin,et al.  Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Brugarolas PBRM1 and BAP1 as novel targets for renal cell carcinoma. , 2013, Cancer journal.

[83]  A. Evans,et al.  Active surveillance of small renal masses: progression patterns of early stage kidney cancer. , 2011, European urology.

[84]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[85]  U. Capitanio,et al.  Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. , 2015, European urology.

[86]  M. Blute,et al.  Surgery for renal cell carcinoma metastases , 2010, Current opinion in urology.

[87]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[88]  J. Patard,et al.  Lymph node dissection in renal cell carcinoma. , 2011, European urology.

[89]  K. Rha,et al.  Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. , 2015, European urology.

[90]  C. Porta,et al.  Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  J. Bissler Everolimus for renal angiomyolipoma in tuberous sclerosis , 2013 .

[92]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[94]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[95]  W. Lowrance,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder Contemporary Use of Partial Nephrectomy at a Tertiary Care Center in the United States , 2022 .

[96]  B. Lane,et al.  Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. , 2013, The Journal of urology.

[97]  J. Manola,et al.  Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[99]  Lisa M. Schwartz,et al.  Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.

[100]  R. Uzzo,et al.  Delayed intervention of sporadic renal masses undergoing active surveillance , 2008, Cancer.

[101]  F. Saad,et al.  Radical versus partial nephrectomy , 2009, Cancer.

[102]  J. Himmelfarb,et al.  Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .

[103]  F. Marshall Obesity and Renal Cell Cancer—a Quantitative Review , 2002 .

[104]  V. Khoo,et al.  Radiotherapy for renal-cell carcinoma. , 2014, The Lancet. Oncology.

[105]  J. Patard,et al.  Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. , 2008, Urology.

[106]  P. Cairns,et al.  Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC , 2013, Epigenetics.

[107]  A. Wein,et al.  Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. , 1994, Radiology.

[108]  Mark W. Ball,et al.  Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. , 2015, The Journal of urology.

[109]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[110]  J. Lam,et al.  Kidney cancer management in 2004: An update for the practicing general urologist , 2004, Current urology reports.

[111]  M. Bader,et al.  Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron‐sparing surgery in patients with renal cell carcinoma , 2009, BJU international.

[112]  R. Motzer,et al.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  W. Linehan,et al.  Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. , 2013, The Journal of urology.

[114]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  I. Derweesh,et al.  Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008 , 2013, BJU international.

[117]  R. Miano,et al.  Robotic radical nephrectomy for renal cell carcinoma: a systematic review , 2014, BMC Urology.

[118]  R. Sega,et al.  Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. , 2007, Current drug safety.

[119]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  J. Bellmunt,et al.  SEOM clinical guidelines for the treatment of renal cell carcinoma , 2014, Clinical and Translational Oncology.

[121]  J. Ferlay,et al.  The changing pattern of kidney cancer incidence and mortality in Europe , 2008, BJU international.

[122]  Paul Russo,et al.  Commentary on The R.E.N.A.L. nephrometry score: A comprehensive standardized system for quantitating renal tumor size, location and depth , 2010 .

[123]  Mark W. Ball,et al.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. , 2015, European urology.

[124]  A. Kuten,et al.  The value of postoperative irradiation in renal cell cancer. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[125]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[126]  David C. Miller,et al.  Partial nephrectomy for small renal masses: an emerging quality of care concern? , 2006, The Journal of urology.

[127]  J. Brugarolas,et al.  Sirolimus in metatastic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  A. Hemal,et al.  Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. , 2007, The Journal of urology.

[129]  John T. Wei,et al.  National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? , 2006, Urology.

[130]  J. Cheville,et al.  Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. , 2015, European urology.

[131]  U. Vaishampayan Cabozantinib as a Novel Therapy for Renal Cell Carcinoma , 2013, Current Oncology Reports.